Life Spine received an investment from Granite Creek Capital Partners. The infusion will enable Life Spine to aggressively pursue its growth initiatives.
“As we sought capital to further accelerate the sales of our Micro-Invasive platforms, Granite Creek stood out as the ideal investment partner given the principals’ knowledge of our business segments and their proclivity to invest in high growth, entrepreneurial companies,” said Michael Butler, CEO of Life Spine.
Mark Radzik, Managing Partner of Granite Creek, said, “Life Spine has a rich portfolio of proprietary products that are sold globally. Further, the company was founded on rapid product development and continues to do the same with a robust pipeline of differentiated spine products and unique procedures that will be commercialized much faster with the benefit of our investment.”
Granite Creek’s previous orthopedic industry investments include funding for Royal Biologics to support employee onboarding, operational growth, product development and acquisitions.
Life Spine received an investment from Granite Creek Capital Partners. The infusion will enable Life Spine to aggressively pursue its growth initiatives.
“As we sought capital to further accelerate the sales of our Micro-Invasive platforms, Granite Creek stood out as the ideal investment partner given the principals’ knowledge of our...
Life Spine received an investment from Granite Creek Capital Partners. The infusion will enable Life Spine to aggressively pursue its growth initiatives.
“As we sought capital to further accelerate the sales of our Micro-Invasive platforms, Granite Creek stood out as the ideal investment partner given the principals’ knowledge of our business segments and their proclivity to invest in high growth, entrepreneurial companies,” said Michael Butler, CEO of Life Spine.
Mark Radzik, Managing Partner of Granite Creek, said, “Life Spine has a rich portfolio of proprietary products that are sold globally. Further, the company was founded on rapid product development and continues to do the same with a robust pipeline of differentiated spine products and unique procedures that will be commercialized much faster with the benefit of our investment.”
Granite Creek’s previous orthopedic industry investments include funding for Royal Biologics to support employee onboarding, operational growth, product development and acquisitions.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
